Full Text View
Tabular View
No Study Results Posted
Related Studies
Relative Bioavailability Of Two Formulations Of Moroctocog Alfa (AF-CC)
This study has been completed.
Study NCT01579903   Information provided by Pfizer

First Received on April 16, 2012.   Last Updated on February 7, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Hemophilia A
More general conditions related to this trial
Blood Coagulation Disorders
Blood Coagulation Disorders, Inherited
Coagulation Protein Disorders
Genetic Diseases, Inborn
Hematologic Diseases
Hemorrhagic Disorders
Interventions listed in this trial
moroctocog alfa (AF-CC)
Additional drug interventions recognized in this trial
Factor VIII
More general drug interventions related to this trial
Coagulants
Hematologic Agents
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Pfizer


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services